Charles River Laboratories Intl. (NYSE: CRL) and Iqvia (NYSE:IQV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.
Get Charles River Laboratories Intl. alerts:
This table compares Charles River Laboratories Intl. and Iqvia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories Intl.||6.78%||24.96%||9.02%|
Earnings & Valuation
This table compares Charles River Laboratories Intl. and Iqvia’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Charles River Laboratories Intl.||$1.86 billion||2.99||$123.35 million||$5.27||22.03|
|Iqvia||$9.74 billion||2.18||$1.31 billion||$4.36||23.57|
Iqvia has higher revenue and earnings than Charles River Laboratories Intl.. Charles River Laboratories Intl. is trading at a lower price-to-earnings ratio than Iqvia, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and price targets for Charles River Laboratories Intl. and Iqvia, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Charles River Laboratories Intl.||0||6||7||0||2.54|
Charles River Laboratories Intl. presently has a consensus price target of $117.77, indicating a potential upside of 1.44%. Iqvia has a consensus price target of $110.38, indicating a potential upside of 7.42%. Given Iqvia’s stronger consensus rating and higher probable upside, analysts clearly believe Iqvia is more favorable than Charles River Laboratories Intl..
Volatility & Risk
Charles River Laboratories Intl. has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Iqvia has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
Insider and Institutional Ownership
97.2% of Charles River Laboratories Intl. shares are owned by institutional investors. Comparatively, 89.8% of Iqvia shares are owned by institutional investors. 2.1% of Charles River Laboratories Intl. shares are owned by insiders. Comparatively, 6.0% of Iqvia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Iqvia beats Charles River Laboratories Intl. on 8 of the 15 factors compared between the two stocks.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.